(object) array( 'id' => '997246', 'url' => 'IT/inflammatory_bowel_disease_(IBD)', 'image' => '', 'title' => 'malattia infiammatoria intestinale (IBD: inflammatory bowel disease)', 'tags' => array ( 0 => 'malattia infiammatoria intestinale (IBD: inflammatory bowel disease)', 1 => 'Health care', 2 => 'Pharmaceutical', 3 => 'Vaccines', 4 => 'U.S. CDC', 5 => '', ), 'term' => 'malattia infiammatoria intestinale (IBD: inflammatory bowel disease)', 'source_id' => 392701, 'type' => 'term', 'namespace' => 1388, 'nstext' => 'IT', 'industry' => array ( 0 => 'Health care', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Vaccines', ), 'company' => array ( 0 => 'U.S. CDC', ), 'lastedit' => '20110408113520', 'part_of_speech' => 'noun', 'creation_user' => 'erotunno', 'special_term' => '', 'definition' => 'Un termine generale per qualsiasi malattia caratterizzata da infiammazione dell\'intestino. Gli esempi includono la colite e morbo di Crohn. I sintomi includono dolore addominale, diarrea, febbre, perdita di appetito e perdita di peso.', 'usage_comment' => 'MT', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1503601809290166278, 'nstext_full' => 'Italian (IT)', 's_attr' => (object) array( 'Term' => 'inflammatory bowel disease (IBD)', 'Definition' => 'A general term for any disease characterized by inflammation of the bowel. Examples include colitis and Crohn\'s disease. Symptoms include abdominal pain, diarrhea, fever, loss of appetite and weight loss.', 'Part of Speech' => 'noun', 'Domain' => 'Documentation', 'Usage Status' => 'New', 'Industry' => 'Health care; Pharmaceutical', 'Product Category' => 'Vaccines', 'Company' => 'U.S. CDC', 'Creation User' => 'Jacobmc', 'Creation Date' => '2010/10/22', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'inflammatory_bowel_disease_(IBD)', )

(object) array( 'id' => '963157', 'url' => 'IT/confidentiality_regarding_trial_participants', 'image' => '', 'title' => 'riservatezza relativa ai partecipanti allo studio', 'tags' => array ( 0 => 'riservatezza relativa ai partecipanti allo studio', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'riservatezza relativa ai partecipanti allo studio', 'source_id' => 30883, 'type' => 'term', 'namespace' => 1388, 'nstext' => 'IT', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20110405170102', 'part_of_speech' => 'noun', 'creation_user' => 'erotunno', 'special_term' => '', 'definition' => 'Si riferisce al mantenimento della riservatezza della prova partecipanti tra cui la loro identità personale e tutte le informazioni mediche personali. Consenso di partecipanti prova per l\'uso di record per scopi di verifica dati dovrebbe essere ottenuto prima del processo e garanzia deve essere dato che verrà mantenuta la riservatezza.', 'usage_comment' => 'MT', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1503601658155761667, 'nstext_full' => 'Italian (IT)', 's_attr' => (object) array( 'Term' => 'confidentiality regarding trial participants', 'Definition' => 'Refers to maintaining the confidentiality of trial participants including their personal identity and all personal medical information. The trial participants\' consent to the use of records for data verification purposes should be obtained prior to the trial and assurance must be given that confidentiality will be maintained.', 'Part of Speech' => 'noun', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Domain' => 'Documentation', 'Usage Status' => 'New', 'Revision User' => 'Hkdoc9', 'Revision Date' => '2010/05/26', 'Creation User' => 'Hkdoc9', 'Creation Date' => '2010/05/26', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'confidentiality_regarding_trial_participants', )

(object) array( 'id' => '1001558', 'url' => 'IT/guillain-barre_syndrome_(GBS)', 'image' => '', 'title' => 'sindrome di Guillain-Barre\'', 'tags' => array ( 0 => 'sindrome di Guillain-Barre\'', 1 => 'Health care', 2 => 'Pharmaceutical', 3 => 'Vaccines', 4 => 'U.S. CDC', 5 => '', ), 'term' => 'sindrome di Guillain-Barre\'', 'source_id' => 392833, 'type' => 'term', 'namespace' => 1388, 'nstext' => 'IT', 'industry' => array ( 0 => 'Health care', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Vaccines', ), 'company' => array ( 0 => 'U.S. CDC', ), 'lastedit' => '20110408164511', 'part_of_speech' => 'noun', 'creation_user' => 'erotunno', 'special_term' => '', 'definition' => 'Una rara malattia neurologica caratterizzata da perdita di riflessi e paralisi temporanea. I sintomi includono debolezza, intorpidimento, formicolio e una maggiore sensibilità che si estende sopra il corpo. Paralisi del muscolo inizia nei piedi e gambe e si muove verso l\'alto per le braccia e le mani. A volte può provocare paralisi muscoli respiratori causando difficoltà respiratorie. Sintomi di solito compaiono nel corso di un giorno e possono continuare a progredire per 3 o 4 giorni fino a 3 o 4 settimane. Recupero inizia entro 2-4 settimane dopo la progressione si arresta. Mentre la maggior parte dei pazienti recupera, circa 15-20% esperienza sintomi persistenti. GBS è fatale nel 5% dei casi.', 'usage_comment' => 'MT', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1503601829179555841, 'nstext_full' => 'Italian (IT)', 's_attr' => (object) array( 'Term' => 'guillain-barre syndrome (GBS)', 'Definition' => 'A rare neurological disease characterized by loss of reflexes and temporary paralysis. Symptoms include weakness, numbness, tingling and increased sensitivity that spreads over the body. Muscle paralysis starts in the feet and legs and moves upwards to the arms and hands. Sometimes paralysis can result in the respiratory muscles causing breathing difficulties. Symptoms usually appear over the course of one day and may continue to progress for 3 or 4 days up to 3 or 4 weeks. Recovery begins within 2-4 weeks after the progression stops. While most patients recover, approximately 15%-20% experience persistent symptoms. GBS is fatal in 5% of cases.', 'Part of Speech' => 'noun', 'Domain' => 'Documentation', 'Usage Status' => 'New', 'Industry' => 'Health care; Pharmaceutical', 'Product Category' => 'Vaccines', 'Company' => 'U.S. CDC', 'Creation User' => 'Jacobmc', 'Creation Date' => '2010/10/22', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'guillain-barre_syndrome_(GBS)', )

(object) array( 'id' => '963686', 'url' => 'IT/phase_i_trials', 'image' => '', 'title' => 'studi di fase I', 'tags' => array ( 0 => 'studi di fase I', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'studi di fase I', 'source_id' => 30916, 'type' => 'term', 'namespace' => 1388, 'nstext' => 'IT', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20110406103044', 'part_of_speech' => 'noun', 'creation_user' => 'erotunno', 'special_term' => '', 'definition' => 'I primi studi per determinare il metabolismo e le azioni farmacologiche dei farmaci nell\'uomo, gli effetti collaterali associati con aumentando le dosi e di acquisire le prime prove di efficacia; possono includere sani partecipanti e/o pazienti.', 'usage_comment' => 'MT', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1503601660281225219, 'nstext_full' => 'Italian (IT)', 's_attr' => (object) array( 'Term' => 'phase i trials', 'Definition' => 'Initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.', 'Part of Speech' => 'noun', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Domain' => 'Documentation', 'Usage Status' => 'New', 'Revision User' => 'Hkdoc9', 'Revision Date' => '2010/05/26', 'Creation User' => 'Hkdoc9', 'Creation Date' => '2010/05/26', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'phase_i_trials', )

(object) array( 'id' => '997108', 'url' => 'IT/association_₅', 'image' => '', 'title' => 'associazione', 'tags' => array ( 0 => 'associazione', 1 => 'Health care', 2 => 'Pharmaceutical', 3 => 'Vaccines', 4 => 'U.S. CDC', 5 => '', ), 'term' => 'associazione', 'source_id' => 392765, 'type' => 'term', 'namespace' => 1388, 'nstext' => 'IT', 'industry' => array ( 0 => 'Health care', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Vaccines', ), 'company' => array ( 0 => 'U.S. CDC', ), 'lastedit' => '20110408112807', 'part_of_speech' => 'noun', 'creation_user' => 'erotunno', 'special_term' => '', 'definition' => 'Il grado a cui è collegato il verificarsi di due eventi o variabili. Associazione descrive una situazione dove la probabilità di accadimento di un evento dipende dalla presenza di un altro evento o variabile. Tuttavia, un\'associazione tra due variabili non implica necessariamente una relazione di causa ed effetto. Il termine associazione e la relazione sono spesso usati in modo intercambiabile. Vedere associazione causale e temporale.', 'usage_comment' => 'MT', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1503601808864444419, 'nstext_full' => 'Italian (IT)', 's_attr' => (object) array( 'Term' => 'association', 'Definition' => 'The degree to which the occurrence of two variables or events is linked. Association describes a situation where the likelihood of one event occurring depends on the presence of another event or variable. However, an association between two variables does not necessarily imply a cause and effect relationship. The term association and relationship are often used interchangeably. See causal and temporal association.', 'Part of Speech' => 'noun', 'Domain' => 'Documentation', 'Usage Status' => 'New', 'Industry' => 'Health care; Pharmaceutical', 'Product Category' => 'Vaccines', 'Company' => 'U.S. CDC', 'Creation User' => 'Jacobmc', 'Creation Date' => '2010/10/22', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'association_₅', )

(object) array( 'id' => '962811', 'url' => 'IT/adverb_clause', 'image' => '', 'title' => 'frase avverbiale', 'tags' => array ( 0 => 'frase avverbiale', 1 => 'Language', 2 => 'Grammar', 3 => '', ), 'term' => 'frase avverbiale', 'source_id' => 776397, 'type' => 'term', 'namespace' => 1388, 'nstext' => 'IT', 'industry' => array ( 0 => 'Language', ), 'category' => array ( 0 => 'Grammar', ), 'lastedit' => '20110405163512', 'part_of_speech' => 'noun', 'creation_user' => 'erotunno', 'special_term' => '', 'definition' => 'Una clausola secondaria che funziona come un avverbio modifica un verbo, aggettivo o avverbio un altro. Risponde a una delle quattro domande: come, quando, dove e perché. Una clausola di avverbio inizia sempre con una collaborazione programmatica. Per esempio, ho visto Tom \' \' quando sono andato al centro commerciale. \' \'', 'usage_comment' => 'MT', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1503601656818827264, 'nstext_full' => 'Italian (IT)', 's_attr' => (object) array( 'Term' => 'adverb clause', 'Definition' => 'A subordinate clause that functions as an adverb to modify a verb, adjective, or another adverb. It answers one of four questions: how, when, where, and why. An adverb clause always begins with a subordinating conjunction. For example, I saw Tom \'\'\'when I went to the mall.\'\'\'', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Language', 'Product Category' => 'Grammar', 'Creation User' => 'en101', 'Creation Date' => '2011/2/21', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'adverb_clause', )

(object) array( 'id' => '958616', 'url' => 'IT/accommodation_₁', 'image' => '', 'title' => 'accomodazione', 'tags' => array ( 0 => 'accomodazione', 1 => 'Medical', 2 => 'Implants and interventional materials', 3 => '', ), 'term' => 'accomodazione', 'source_id' => 45545, 'type' => 'term', 'namespace' => 1388, 'nstext' => 'IT', 'industry' => array ( 0 => 'Medical', ), 'category' => array ( 0 => 'Implants and interventional materials', ), 'lastedit' => '20110405104738', 'part_of_speech' => 'noun', 'creation_user' => 'erotunno', 'special_term' => '', 'definition' => 'un aumento della soglia di stimolazione di un nervo dovuta a contatto', 'usage_comment' => 'MT', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1503601638686851075, 'nstext_full' => 'Italian (IT)', 's_attr' => (object) array( 'Term' => 'accommodation', 'Definition' => 'an increase in the stimulation threshold of a nerve due to contact', 'Domain' => 'Documentation; Marketing; Other', 'Industry' => 'Medical', 'Part of Speech' => 'noun', 'Product Category' => 'Implants and interventional materials', 'Usage Status' => 'New', 'Revision User' => 'Uwe', 'Revision Date' => '2010/6/11', 'Creation User' => 'Uwe', 'Creation Date' => '2010/6/11', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'accommodation_₁', )

(object) array( 'id' => '962808', 'url' => 'IT/to', 'image' => '', 'title' => 'a/al/allo/alla', 'tags' => array ( 0 => 'a/al/allo/alla', 1 => 'Language', 2 => 'Dictionaries', 3 => '', ), 'term' => 'a/al/allo/alla', 'source_id' => 730517, 'type' => 'term', 'namespace' => 1388, 'nstext' => 'IT', 'industry' => array ( 0 => 'Language', ), 'category' => array ( 0 => 'Dictionaries', ), 'lastedit' => '20110405163504', 'part_of_speech' => 'preposition', 'creation_user' => 'erotunno', 'special_term' => '', 'definition' => 'Funzione Parole; preposizione; SB o sth. andando da qualche parte.', 'usage_comment' => 'MT', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1503601656817778691, 'nstext_full' => 'Italian (IT)', 's_attr' => (object) array( 'Term' => 'to', 'Definition' => 'Function words; preposition; sb. or sth. going somewhere.', 'Part of Speech' => 'preposition', 'Usage Status' => 'New', 'Industry' => 'Language', 'Product Category' => 'Dictionaries', 'Context' => 'They will go to Baguio tomorrow. Pupuntà sila sa Baguio búkas. Sie werden morgen nach Baguio gehen.', 'Creation User' => 'climatepatrol', 'Creation Date' => '2011/2/12', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'to', )

(object) array( 'id' => '963639', 'url' => 'IT/natural_history_study', 'image' => '', 'title' => 'studio storico naturale', 'tags' => array ( 0 => 'studio storico naturale', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'studio storico naturale', 'source_id' => 30910, 'type' => 'term', 'namespace' => 1388, 'nstext' => 'IT', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20110405175012', 'part_of_speech' => 'noun', 'creation_user' => 'erotunno', 'special_term' => '', 'definition' => 'Studio dello sviluppo naturale di qualcosa (come un organismo o una malattia) in un periodo di tempo.', 'usage_comment' => 'MT', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1503601660051587075, 'nstext_full' => 'Italian (IT)', 's_attr' => (object) array( 'Term' => 'natural history study', 'Definition' => 'Study of the natural development of something (such as an organism or a disease) over a period of time.', 'Part of Speech' => 'noun', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Domain' => 'Documentation', 'Usage Status' => 'New', 'Revision User' => 'Hkdoc9', 'Revision Date' => '2010/05/26', 'Creation User' => 'Hkdoc9', 'Creation Date' => '2010/05/26', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'natural_history_study', )

(object) array( 'id' => '962325', 'url' => 'IT/allomorph', 'image' => 'allo-1371563638.jpg', 'title' => 'allomorfo', 'tags' => array ( 0 => 'allomorfo', 1 => 'Language', 2 => 'Grammar', 3 => '', ), 'term' => 'allomorfo', 'source_id' => 791752, 'type' => 'term', 'namespace' => 1388, 'nstext' => 'IT', 'industry' => array ( 0 => 'Language', ), 'category' => array ( 0 => 'Grammar', ), 'lastedit' => '20130618135830', 'part_of_speech' => 'noun', 'creation_user' => 'erotunno', 'special_term' => '', 'definition' => 'A variant pronunciation of a morpheme, especially when it involves a change of phonemes. Allomorphs which are phonologically related provide cases of phonological alternation, which can be important evidence as a part of phonological analysis. Allomorphs which do not have a phonological relationship are termed suppletive. For example, the English negative prefix "in-" of words like "in-tolerable" or "in-admissible" has the variant form (allomorph) "im-", which appears in such forms as "im-possible".', 'usage_comment' => 'MT', 'glossary' => '', 'width' => 230, 'height' => 219, '_version_' => 1503601654857990145, 'nstext_full' => 'Italian (IT)', 's_attr' => (object) array( 'Term' => 'allomorph', 'Definition' => 'A variant pronunciation of a morpheme, especially when it involves a change of phonemes. Allomorphs which are phonologically related provide cases of phonological alternation, which can be important evidence as a part of phonological analysis. Allomorphs which do not have a phonological relationship are termed suppletive. For example, the English negative prefix "in-" of words like "in-tolerable" or "in-admissible" has the variant form (allomorph) "im-", which appears in such forms as "im-possible".', 'Domain' => 'Documentation', 'Industry' => 'Language', 'Part of Speech' => 'noun', 'Product Category' => 'Grammar', 'Usage Status' => 'New', 'Creation User' => 'CarmenChavarri', 'Creation Date' => '2011/2/23', 'Source Lang' => '1180', 'Sample Image' => 'allo-1371563638.jpg', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'allomorph', )